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Osaterone acetate (17␣-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione; OA 1 ) is a new steroidal antiandrogen (Fig. 1 ). This compound has been shown to reduce the volume of the prostate in rats (Honma et al., 1994b; Mieda et al., 1994) and dogs (Takezawa et al., 1992 (Takezawa et al., , 1993 . OA is 5 times more potent than chlormadinone acetate (Takezawa et al., 1992) , which has been used in the clinical treatment of prostatic hypertrophy and prostatic cancer (Brennan and Kraay, 1963) . Chlormadinone acetate has been reported to be converted rapidly to 2-hydroxylated and 3-hydroxylated compounds (Honma et al., 1977) . OA is an analog of chlormadinone acetate, 2-oxachlormadinone acetate. Incorporation of an oxygen atom into the steroid nucleus at C 2 might affect the metabolism.
The pharmacokinetic characteristics of OA in rats have been studied in great detail (Honma et al., 1994a; Minato and Honma, 1994) . The plasma half-life of OA was 2.0 h after a single intravenous administration. In spite of the incorporation of an oxygen atom into the steroid nucleus at C 2 , metabolism could not be avoided. At 1 h after the administration, unchanged compound in plasma represented only 40.9% of the total radioactivity, and the major metabolite 17␣-acetoxy-6-chloro-15␤-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione (15␤-OH OA) represented 57.7% (Honma et al., 1994a ). However, the major metabolite 15␤-OH OA is pharmacologically active (Honma et al., 1994b) . The mean excretion of radioactivity in the feces accounted for 90% of the dose, and the enterohepatic recirculation was 75% (Honma et al., 1994a) . On the other hand, the pharmacokinetics in dogs has not been investigated. The objective of the present study was to explore the pharmacokinetics and biliary excretion of OA in dogs.
animals were fitted with a canvas vest to protect the skin fittings and catheters. The dogs were allowed at least 7 days to recover from the medical treatment before testing started. The dogs remained conscious and healthy throughout the experiment.
[ 14 C]OA (400 kBq/mg, 0.25 mg/ml) dissolved in saline containing 50% DMSO was administered (0.25 mg/100 kBq/kg) into the saphenous vein. Plasma samples were obtained at 1, 2, 3, 6, 12, 24, 48, 72, 168 , and 240 h. The schedule for biliary collection was 0 to 3, 3 to 12, 12 to 24, 24 to 48, 48 to 72, and 72 to 96 h. At 96 h postdosing, both catheters were joined, and the bile was recirculated. Urine and feces samples were collected every 24 h up to 240 h. All samples were kept frozen until analyzed. Storage of OA in bile at Ϫ20°C did not result in any detectable decomposition for more than 6 months.
Determination of Radioactivity. Total radioactivity in the plasma, urine, and bile was quantified in a liquid scintillation counter (LSC-3500; Aloka Co., Tokyo, Japan) after addition of 5 ml of Insta-Gel (Packard BioScience B.V., Groningen, Holland). The counting efficiency was determined by external standardization. Fecal samples were suspended in an appropriate quantity of water and homogenized with an Ultra-turrax mechanical homogenizer (Janke & Kunkel, Stufen, Germany.) . Aliquots of homogenate were dried in vacuo overnight and combusted in an auto-oxidizer (ASC-113; Aloka Co.). The radioactivity in the combustion products was determined by trapping the liberated 14 CO 2 in Carbosorb (Packard BioScience B.V.) and mixing with Permafluoro V (Packard BioScience B.V.), followed by liquid scintillation counting.
The radioactivity in plasma was expressed as nanograms of equivalents of unchanged compound per milliliter. The radioactivity in bile, urine, and feces was expressed as a percentage of the dose. Sample Preparation for GC-MS with Selected Ion Monitoring. To each plasma sample (1 ml) was added [2,3- 18 O 2 , 1␣-2 H]OA (25 ng) as an internal standard, followed by 1 ml of distilled water and 0.5 ml of 2 M HCl. The resulting solution was applied to a Bond Elut C 18 cartridge (3 ml; Varian, Palo Alto, CA) that had been rinsed with 6 ml of both methanol and distilled water. The cartridge was washed with 4 ml of distilled water and 2 ml of 30% (v/v) acetonitrile and then eluted with 2.5 ml of 60% (v/v) acetonitrile. After evaporating the solvent in vacuo at 50°C with a centrifugal evaporator, the residue was dissolved in 60 l of 50% (w/w) dimethylethylsilyl imidazole in benzene and allowed to stand for 3 h at 60°C. Then, the solution was diluted with 0.5 ml of 25% (v/v) hexane in benzene, and applied to a Bond Elut CN cartridge (3 ml; Varian) that had been rinsed with 10 ml of 25% (v/v) hexane in benzene. The cartridge was washed with 2 ml of 25% (v/v) hexane in benzene and eluted with 2 ml of ethyl acetate/benzene (1:10, v/v). After evaporating the solvent under a stream of nitrogen, the residue was dissolved in 50 l of acetone and subjected to GC-MS-SIM.
To the urine samples (0.25ϳ1.0 ml) was added [2,3-18 O 2 , 1␣-2 H]OA (100 ng) as an internal standard, followed by 1 ml of distilled water and 0.5 ml of 2 M HCl. The solution was then treated as described above and subjected to GC-MS-SIM.
To each bile sample (0.1 ml) was added [2,3-18 O 2 , 1␣-2 H]OA (100 ng) as an internal standard, followed by 1 ml of distilled water and 0.5 ml of 2 M HCl. The solution underwent extraction using a Bond Elut C 18 cartridge, as described above. After evaporating the solvent in vacuo at 50°C with a centrifugal evaporator, the residue was reconstituted in 1 ml of 1% NaHCO 3 , extracted twice with 4 ml of chloroform, and dried over anhydrous sodium sulfate. Following filtration, concentration, and evaporation to dryness in vacuo, a dry residue was obtained to which 60 l of 50% (w/w) dimethylethylsilyl imidazole in benzene was added. The resulting solution was allowed to stand for 3 h at 60°C. Then, the solution was diluted with 0.5 ml of 25% (v/v) hexane in benzene and applied to a Bond Elut CN cartridge (3 ml; Varian) that had been rinsed with 10 ml of 25% (v/v) hexane in benzene. The cartridge was then washed with 2 ml of 25% (v/v) hexane in benzene and eluted with 2 ml of ethyl acetate/benzene (1:10, v/v). After evaporating the solvent under a stream of nitrogen, the residue was dissolved in 50 l of acetone and subjected to GC-MS-SIM.
GC-MS-SIM. GC-MS-SIM analysis was conducted on a Hitachi M-80 instrument (Tokyo, Japan) equipped with a data processor (M-003). The GC column was made of glass (0.5-m ϫ 6-mm i.d.) packed with 2% OV-17 (GL science, Tokyo, Japan). The column temperature was set at 247°C. The mass spectrometer was operated in the electron ionization mode with helium (30 ml/min) as the carrier gas. The ionization voltage was 20 eV. SIM was performed on the fragment ions at m/z 303 and 308 for OA and [2, 18 O 2 , 1␣-2 H]OA, respectively. Radioluminography. The radioluminography equipment consisted of an imaging plate (IP; 20 ϫ 40 cm) for 14 C, a magazine cassette 14 C, a Fuji shield box, and a bioimaging analyzer system (FUJIX BAS-2000; Fuji Film, Kanagawa, Japan). The IP was used to record the radioactivity observed on the TLC plates, and the FUJIX BAS-2000 bioimaging analyzer was used to determine the distribution of radioactivity recorded on the IP. Image analysis of the radioactivity profiles on TLC plates (Kieselgel 60F 254 ; 20 ϫ 20 cm, 0.25 mm thick; Merck) was conducted after two-dimensional TLC of bile with chloro- 
FIG. 2. Plasma concentration versus time profiles of osaterone acetate (a) and total radioactivity (b) after a single intravenous administration of [ 14 C]OA (0.25 mg/kg) to intact (E) and biliary fistula (F) dogs.
Each point represents the mean Ϯ S.D. of four experiments. kg/day) in saline containing 50% DMSO were administered to the four dogs with biliary fistulas for 4 days. Bile was collected up to 24 h after the final dose. The combined samples from the four dogs were kept frozen until analyzed. Storage of OA, 15␤-OH OA, 21-OH OA, and 21-OH OA-21-glucuronide in bile at Ϫ20°C did not result in any detectable decomposition. At room temperature, 21-OH OA in solution is gradually changed to 21-acetoxy-6-chloro-17␣-hydroxy-2-oxa-4,6-pregnadiene-3,20-dione by intramolecular acetyl rearrangement.
The bile (2 liters) was adjusted to pH 4 with 2 M HCl, loaded onto an Amberlite XAD-2 column (50 ϫ 7.5 cm; Supelco, Bellefonte, PA), then washed with 3.5 liters of distilled water, and eluted with 5 liters of methanol. The methanol was evaporated to dryness, and the residue (54.1 g) was reconstituted in 300 ml of distilled water. The solution was adjusted to pH 4 with HCl and extracted with 240 ml of ethyl acetate twice. Compounds A, B, and C were isolated from the ethyl acetate phase by preparative TLC (chloroform/acetone, 20:1, v/v). The aqueous phase, containing compound D, was evaporated to dryness; the residue (38.5 g) was reconstituted in 80 ml of 20% methanol, and the solution was loaded onto a Sephadex LH-20 column (40 ϫ 5 cm; Amersham Biosciences AB, Uppsala, Sweden). After washing the column with 45 ml of 20% methanol, the radioactive fraction was eluted with 20 ml of 20% methanol. The radioactive fraction was evaporated, and the residue (29.0 g) was dissolved in chloroform/methanol/water (35:15:3, v/v/v) and applied to a silica-gel column (55 ϫ 3.5 cm; Wako-gel C-200; Wako Pure Chemicals, Tokyo, Japan). After washing the column with 1520 ml of chloroform/methanol/water (35:15:3, v/v/v), elution was carried out with 1320 ml of mixed solvent. The solvent was evaporated, and the residue was separated on a Sephadex LH-20 column (55 ϫ 3.5 cm), as described above, and a radioactive residue (13.0 g) was obtained. The radioactive residue was dissolved in a small amount of methanol/acetonitrile/water (3:3:4, v/v/v) and 3.6 Ϯ 0.5 6.9 Ϯ 1.1 10.5 Ϯ 0.9 3.0 Ϯ 1.1 1.1 Ϯ 0.6 6.9 Ϯ 1.9 11.0 Ϯ 2.2 96-120 3.6 Ϯ 1.3 5.5 Ϯ 1.4 9.1 Ϯ 1.6 3.2 Ϯ 1.1 1.7 Ϯ 0.7 11.8 Ϯ 1.8 120-144 2.8 Ϯ 0.7 5.1 Ϯ 0.7 7.9 Ϯ 1.1 2.9 Ϯ 0.5 1.7 Ϯ 0.5 11.5 Ϯ 1.9 144-168 2.6 Ϯ 0. The residue was dissolved in a small amount of distilled water and applied to a DEAE-Sephadex A-25 column (45 ϫ 2 cm, DEAE-Sephadex A-25; Amersham Biosciences AB) that had been prepared with distilled water. The column was washed with 50 ml of distilled water and then eluted with a linear gradient obtained by mixing 500 ml of 1 M NaCl with 500 ml of distilled water. A flow rate of approximately 15 ml/h was maintained. The radioactive fraction was chromatographed on a preparative-HPLC column (YMC-pack SH-343-5; YMC Co.). The obtained radioactive residue was subjected to HPLC (column, 250 ϫ 20-mm i.d.; YMC-pack AQ-312; YMC Co.). Compound D (10.8 mg) was obtained after evaporation of the solvent from the eluate. An aliquot (0.7 mg) of compound D obtained was dissolved in a mixture of 10 ml of benzene/methanol solvent (4:1, v/v), and then mixed with 10 ml of trimethylsilyl-diazomethane. The reaction mixture was stirred at room temperature for 2 h. Volatile compounds were then removed in vacuo. The residue obtained was treated with 10 ml of pyridine and 10 ml of acetic acid anhydride at room temperature for 48 h. The concentration in vacuo gave the derivatized compound, which was subjected to purification by silica-gel chromatography (with benzene/methanol, 10:1, v/v, as the eluent) to provide the pure derivative. The assumed structure of compound D was confirmed by comparison of its mass spectrum with that of the synthetic reference compound.
Characterization of compounds A to C was performed by proton NMR(90 MHz) and mass spectrometry. Proton NMR spectra were recorded on a Hitachi R-90H instrument or a JEOL GX-500 instrument (Jasco, Tokyo, Japan). Chemical shifts were expressed relative to the tetramethylsilane used as an internal standard. Mass spectra were obtained using a Shimadzu (Kyoto, Japan) GCMS-QP1000 spectrometer operated in the electron impact ionization mode.
Characterization of compound D was performed by Proton NMR, 13 C NMR, and fast atom bombardment-mass spectrometry. Proton and 13 C NMR spectra were obtained on a JNM-LA 500 spectrometer (Jasco) as solutions in deuterated methanol or deuterated pyridine. Chemical shifts were expressed relative to the tetramethylsilane used as an internal standard. Proton-NMR spectra were recorded at 500 MHz.
13 C NMR spectra were recorded at 400 MHz. Mass spectra and high-resolution mass spectra were obtained using a VG ZAB-HF mass spectrometer (VG Analytical, Manchester, UK) operated in the atom bombardment mode. The spectra were obtained using xenon atoms at 8 kV, glycerol as the matrix, and in the negative ion mode.
Synthesis of Methyl(17␣-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione-21-yl-2,3,4-O-triacetyl-␣-D-glucopyranosid)uronate. Freshly prepared AgCO 3 (50 mg) was added to a solution of 21-OH OA (30 mg) in anhydrous benzene (5 ml). Then methyl(1␣-bromo-1-deoxy-2,3,4-O-triacetyl-␣-D-glucopyranuorate) (70 mg) was added, followed by stirring at room temperature for 72 h. The resulting precipitate was removed by filtration. After evaporating the filtrate under reduced pressure, the oily residue was subjected to preparative TLC using benzene/methanol (9:1, v/v) as a developing solvent. The zone corresponding to the target compound was scrapped from the plate. Extraction with ethyl acetate gave 57.2 mg of methyl(17␣-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione-21-yl-2Ј,3Ј,4Ј-O-triacetyl-␣-D-glucopyranosid)uronate.
Data Analysis. Model-independent evaluation of the pharmacokinetic parameters from the plasma OA concentration-time profiles for all individuals was performed using PAG-CP (ASTA Medica, Osaka, Japan). In biliary fistula dogs, the area under the plasma concentration time curve (AUC) was calculated by the linear trapezoidal rule through the point just before restart of normal bile flow (72 h after dosing). In intact dogs, pharmacokinetic parameters were calculated through 240 h after administration (the entire blood collection period). The mean residence time was calculated as the ratio from the first moment curve and AUC, and the total plasma clearance was calculated as the ratio of dose and AUC. All parameter estimates are reported as mean Ϯ S.D. Differences in AUC 0 -72 estimates between intact and biliary fistula dogs 
Results

Plasma Concentration Profiles.
The plasma concentration profiles of OA and total radioactivity in intact and biliary fistula dogs are shown in Fig. 2, a and b , respectively. A biexponential decline was observed in plasma OA concentrations. OA exhibited a very long half-life of 197.9 Ϯ 109.9 h in intact dogs. There were not significant differences in the plasma concentration profiles of OA and total radioactivity. OA accounted for almost all the plasma radioactivity. Model-independent pharmacokinetic analyses were performed based on the data of OA. The results of pharmacokinetic analyses are summarized in Table 1 . There was no statistical significance in AUC 0 -72 between intact and biliary fistula dogs.
Excretion Studies. The excretion data after a single intravenous administration of [ 14 C]OA to intact and biliary fistula dogs are given in Table 2 . In intact dogs, 14.9 Ϯ 2.1 and 23.9 Ϯ 3.6% of administered radioactivity were recovered in the urine and feces over 72 h, respectively. In biliary fistula dogs, 20.4 Ϯ 8.8, 4.6 Ϯ 0.3, and 30.2 Ϯ 7.0% of administered radioactivity were recovered in the urine, feces, and bile over 72 h, respectively. Table 3 shows excretion of OA and metabolites (total radioactivity Ϫ OA) and the excretion rate of total radioactivity in bile and urine in biliary fistula dogs. Unchanged compound (OA) accounted for about one third of the total radioactivity in bile and urine over 96 h. The mean biliary excretion rate of total radioactivity was 0.39 Ϯ 0.06% of the dose/h. The rate was approximately constant from 12 h after the administration. Accordingly, the biliary excretion rate of total radioactivity was slow and steady.
Identification of Biliary Metabolites. Two-dimensional TLC-radioluminography of the biliary metabolites is shown in Fig. 3 . Four main spots (compounds A-D) were observed. Compounds A, B, and C were identified as OA, 21-OH OA, and 15␤-OH OA, respectively, by spectroscopic analysis and comparison with authentic standard samples. The specific data for compounds A, B, and C were shown in Table 4 . Proton NMR (500 MHz) and MS spectra of compound D are shown in Figs. 4 and 5, respectively. Table 5 summarizes the 13 C NMR chemical shifts of compound D and reference compounds. A comparison of the 13 C NMR spectrum of 21-OH OA with that of compound D indicated that the C-21 signal was displaced downfield by 6.91 ppm following glucuronidation, while the other carbon resonances of both compounds appeared at essentially the same positions. A similar chemical shift following glucuronidation has been reported previously for 24-nor-5␤-cholestane-3␣,7␣,12␣,25-tetrol-3-glucuronide (Kuramoto et al., 1993) and 5␤-cholestane-3␣,7␣,12␣,25-tetrol-3-glucuronide (Kibe et al., 1981) . Comparison of MS spectra between the methyl-acetyl derivative of compound D and the authentic gluco- 
Discussion
Marked species differences in pharmacokinetics have been found between rats and dogs. The half-life of OA in intact dogs was very long (197.9 Ϯ 109.9 h) compared with that in rats (2.04 h) (Honma et al., 1994a) . There were no significant differences between OA and total radioactivity profiles shown in Fig. 2 . OA accounted for almost all the plasma radioactivity. In rats, unchanged compound in plasma represented only 40.9% of the total radioactivity, and the metabolite (15␤-OH OA) represented 57.7% at 1 h after the administration (Honma et al., 1994a) . A lower rate of metabolism in dogs would be expected to be associated with the species differences in half-life.
To understand the contribution of enterohepatic recirculation, the pharmacokinetics of OA was investigated after intravenous bolus administration to intact and biliary fistula dogs. Within 72 h after a single intravenous administration of [ 14 C]OA in biliary fistula dogs, 30.2 Ϯ 7.0 and 20.4 Ϯ 8.8% of the radioactivity is recovered in bile and urine, respectively. This confirms that bile is a major excretion route of OA and its metabolites. The biliary excretion rates was much slower in dogs (0.42 Ϯ 0.10% of the dose/h) than in rats (0.81 Ϯ 0.23% of the dose/h) (Minato and Honma, 1994) . The difference in the biliary excretion rate would be associated with the longer elimination half-life of OA in dogs. Furthermore, the fecal excretion in intact dogs was 23.9%, whereas in biliary fistula dogs the combined fecal and biliary excretion was 34.8%. The difference also suggested that a significant amount of biliary recycling occurs in dogs.
OA accounted for almost all the plasma radioactivity. On the other hand, only one-third of radioactivity in the bile was identified as being due to unchanged compound. Four radioactive compounds were observed in the bile. Compounds A, B, and C were identified as unchanged compound, 21-OH OA, and 15␤-OH OA, respectively, by spectroscopic analysis and comparison with authentic standard samples. The major biliary metabolite (compound D) was identified as a glucuronide of 21-OH OA. The authentic standard sample (17␣-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione-21-yl-2Ј,3Ј,4Ј-O-triacetyl-␣-D-glucopyranosid)uronate) cannot be hydrolyzed to the glucuronide of 21-OH OA. Because the aglycone has an ester bond in the A ring, 17␣-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione-21-yl-2Ј,3Ј,4Ј-O-triacetyl-␣-D-glucopyranosid)uronate was used as a suitable compound for the direct comparison. It was believed that the metabolites are excreted into bile passively and do not diffuse back into the systemic circulation following enterohepatic recirculation. Therefore, further studies of the pharmacokinetics are required.
The slow and steady excretion of OA may result in slow elimination from the systemic circulation, and active transport may also be involved. It is generally believed that most steroid hormones are substrates for P-glycoprotein (Pgp) (Ueda et al., 1992; Nakayama et al., 1999) . Pgp is expressed in normal tissues and is found on the luminal surface of the transporting epithelia of liver biliary hepatocytes, kidney proximal tubules, and the small intestine. Pgp has a relatively broad substrate specificity (Tanaka et al., 1996; Arimori et al., 1998) . The degree of recognition by Pgp might be highly dependent upon the structure of the compound involved. The degree of Pgp recognition can be markedly affected by the presence of only a single oxygen atom in a steroid. For instance, the presence of a 17␣-hydroxyl group is associated with a greater shift. Similarly, there is evidence that progesterone, which does not have any hydroxyl groups in its structure, is not transported (Yang et al., 1990; Bourgeois et al., 1993) . Progesterone has been shown to be capable of reversing Pgp-dependent drug resistance, inhibiting photoaffinity labeling of Pgp by azidopine, and serving as a photoaffinity label for the human form of Pgp (Qian and Beck, 1990; Yang et al., 1990) . Therefore, it is evident that progesterone can bind to Pgp, even if it is not transported. In general, the relative ability of steroids to reverse drug resistance and inhibit drug binding to Pgp has been found to be highly dependent upon the hydrophobicity of the individual steroids (Yang et al., 1989; Barnes et al., 1996) . The present article has described the pharmacokinetics and biliary excretion of OA in dogs. Biliary excretion is the major excretion route. The longer elimination half-life of OA in dogs relative to rats may be due to the slower metabolism, slow biliary excretion, and enterohepatic recirculation.
